Cargando…

Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma

Mature T-cell lymphomas (MTCLs) represent a heterogeneous group of aggressive non-Hodgkin lymphomas comprising different entities. Anthracycline-based regimens are considered the standard of care in the front-line treatment. However, responses to these approaches have been neither adequate nor durab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magni, Martina, Paolizzi, Chiara, Monfrini, Chiara, Vella, Cristina, Corradini, Paolo, Carniti, Cristiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999036/ https://www.ncbi.nlm.nih.gov/pubmed/35409194 http://dx.doi.org/10.3390/ijms23073834

Ejemplares similares

Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
por: Magni, Martina, et al.
Publicado: (2019)

Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
por: Monfrini, Chiara, et al.
Publicado: (2022)

Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti‐CD19 chimeric antigen receptor T‐cell efficacy
por: Guidetti, Anna, et al.
Publicado: (2022)

SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma
por: Rusconi, Chiara, et al.
Publicado: (2020)

Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics
por: Calabretta, Eleonora, et al.
Publicado: (2022)

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy
por: Castoldi, Francesca, et al.
Publicado: (2018)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Advances in anthracycline chemotherapy : epirubicin /
Publicado: (1984)

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas
por: Briski, R, et al.
Publicado: (2014)

Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy
por: Hung, Olivia Y, et al.
Publicado: (2015)

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021)

T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
por: Marasco, Vincenzo, et al.
Publicado: (2021)

DNA damage independent inhibition of NF-κB transcription by anthracyclines
por: Chora, Angelo Ferreira, et al.
Publicado: (2022)

Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections
por: Corradini, Paolo, et al.
Publicado: (2020)

Coronary microcirculation damage in anthracycline cardiotoxicity
por: Galán-Arriola, Carlos, et al.
Publicado: (2021)

Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy
por: Kim, Yu Ri, et al.
Publicado: (2011)

Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
por: Edwardson, Derek W., et al.
Publicado: (2015)

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

The dual role of ferroptosis in anthracycline-based chemotherapy includes reducing resistance and increasing toxicity
por: Zhao, Jiazheng, et al.
Publicado: (2023)

Anthracycline-induced cytotoxicity in the GL261 glioma model system
por: Tavener, Amber M., et al.
Publicado: (2021)

The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer
por: Brouwer, Thomas P., et al.
Publicado: (2022)

Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma
por: Luminari, Stefano, et al.
Publicado: (2011)

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma
por: AbouYabis, Abeer N., et al.
Publicado: (2011)

RBL2 Regulates Cardiac Sensitivity to Anthracycline Chemotherapy
por: Xia, Peng, et al.
Publicado: (2023)

CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
por: Maura, Francesco, et al.
Publicado: (2020)

S228: POSITRON EMISSION TOMOGRAPHY EVALUATION IN A LARGE GROUP OF PATIENTS AFFECTED BY RELAPSED/REFRACTORY B-CELL LYMPHOMAS TREATED WITH ANTI-19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS THERAPY (CART SIE).
por: Dodero, Anna, et al.
Publicado: (2023)

Application Effect and Evaluation of Two-Dimensional Speckle Tracking Imaging on Myocardial Damage in Patients with Malignant Lymphoma Treated with Anthracyclines
por: Bai, Chunqiang, et al.
Publicado: (2021)

Cardiotoxicity by Anthracycline Regimen Chemotherapy Prolonged T Peak to T End Interval
por: Iqbal, Mohammad, et al.
Publicado: (2020)

P1081: A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE
por: Chiappella, Annalisa, et al.
Publicado: (2023)

An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline
por: Sarocchi, Matteo, et al.
Publicado: (2018)

Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy
por: Klimiuk, Paweł, et al.
Publicado: (2021)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy
por: Shima, Hiroaki, et al.
Publicado: (2022)

Retracted: Application Effect and Evaluation of Two-Dimensional Speckle Tracking Imaging on Myocardial Damage in Patients with Malignant Lymphoma Treated with Anthracyclines
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers
por: Fucà, Giovanni, et al.
Publicado: (2020)

Cardiomyopathy in a dog with multicentric lymphoma following treatment with several anthracyclines
por: Tagawa, Michihito, et al.
Publicado: (2021)

Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma
por: Colia, Vittoria, et al.
Publicado: (2017)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
por: Rusconi, Chiara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2d0lonkkpqcr6v5hkaki5663cb